Table 1.
Baseline characteristics of non CKD, CKD, hemodialysis and peritoneal dialysis patients involved in the study (N = 114).
Table 2.
Dialysis adequacy for HD and DP patients.
Figure 1.
Plasma ZAG concentration is increased in end stage renal disease patients.
ZAG concentration was quantified in plasma from non-CKD subjects (N = 18), chronic kidney disease (CKD stage 1 to 5, N = 71), hemodialysis (HD, N = 17) and peritoneal dialysis (PD, N = 8) patients by enzyme immunoassay. eGFR was estimated using CKD EPI formula as described in methods. Data are presented as median (interquartile range). Different letters indicate a significant difference at the P<0.05 level.
Figure 2.
Plasma ZAG concentration increases during hemodialysis session.
ZAG concentration was quantified by enzyme immunoassay before and after an hemodialysis session in ESRD patients (N = 8). ZAG concentrations were corrected for hemoconcentration as described in methods. Differences between pre and post dialysis concentrations were considered significant at the P<0.05 level (Wilcoxon test for paired samples). Abbreviation: HD, hemodialysis.
Figure 3.
Plasma ZAG concentration in CKD-5 patients with a diagnostic of protein-energy wasting.
The boxes indicate the range (i.e. min to max) and the line indicate the median. Note that no difference was found to be significant at the P<0.05 level. Abbreviation: PEW, protein-energy wasting.
Figure 4.
Plasma glycerol concentration in non-CKD and CKD patients.
Plasma glycerol was measured as an index of lipolysis in 17 non-CKD patients, 6 CKD-2, 4 CKD-4 and 12 CKD-5 patients. A) plasma glycerol concentration B) Plasma glycerol, concentration normalized to body fat mass as described in methods. No difference was found to be significant at the P<0.05 level using Kruskall & Wallis test.
Table 3.
Univariate correlations with ZAG concentrations.
Table 4.
Multiple linear regression showing association with plasma ZAG concentration (r2 = 0.406, P<0.001).
Table 5.
Characteristics of CKD-5 patients with PEW.